Carboplatin-induced gene expression changes in vitroare prognostic of survival in epithelial ovarian cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1755-8794
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Carboplatin-induced gene expression changes in vitroare prognostic of survival in epithelial ovarian cancer ; volume:1 ; number:1 ; day:28 ; month:11 ; year:2008 ; pages:1-12 ; date:12.2008
BMC medical genomics ; 1, Heft 1 (28.11.2008), 1-12, 12.2008
- Urheber
-
Konstantinopoulos, Panagiotis A.
- Beteiligte Personen und Organisationen
-
Fountzilas, Elena
Pillay, Kamana
Zerbini, Luiz F.
Libermann, Towia A.
Cannistra, Stephen A.
Spentzos, Dimitrios
SpringerLink (Online service)
- DOI
-
10.1186/1755-8794-1-59
- URN
-
urn:nbn:de:1111-2016071642922
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Konstantinopoulos, Panagiotis A.
- Fountzilas, Elena
- Pillay, Kamana
- Zerbini, Luiz F.
- Libermann, Towia A.
- Cannistra, Stephen A.
- Spentzos, Dimitrios
- SpringerLink (Online service)
Ähnliche Objekte (12)
MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer
Endometriosis is the independent prognostic factor for survival in Chinese patients with epithelial ovarian carcinoma
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
Impact of diabetes mellitus on epithelial ovarian cancer survival
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma
Carboplatin hypersensitivity in relapsed ovarian carcinoma: A therapeutic challenge
Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer
The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer
MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer
Endometriosis is the independent prognostic factor for survival in Chinese patients with epithelial ovarian carcinoma
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
Impact of diabetes mellitus on epithelial ovarian cancer survival
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma
Carboplatin hypersensitivity in relapsed ovarian carcinoma: A therapeutic challenge
Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer
The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer
MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer
Endometriosis is the independent prognostic factor for survival in Chinese patients with epithelial ovarian carcinoma
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
Impact of diabetes mellitus on epithelial ovarian cancer survival
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma
Carboplatin hypersensitivity in relapsed ovarian carcinoma: A therapeutic challenge
Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer